Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: J Am Coll Surg. 2012 Feb 22;214(4):700–708. doi: 10.1016/j.jamcollsurg.2011.12.034

Figure 4.

Figure 4

IL-12-priming during CD8+ T cell activation leads to significantly enhanced anti-tumor activity. Mice with s.c. B16 tumors were treated on day 12 as indicated with CTX. On day 13, mice were adoptively transferred with pmelIL-12 (3×106) or pmelsham (3×106) T cells. Tumors were measured blindly twice weekly. Each line represents one mouse.